Mitochondrial dysfunction is increasingly recognized as one of the twelve hallmarks of aging¹ and is thought to contribute to many of the physiological changes that occur over time. Beyond their role in cellular energy production, mitochondria regulate redox balance, cellular signaling, inflammation, and vascular function. As mitochondrial function declines with age, cells may become less efficient at maintaining these processes, reducing tissue resilience and contributing to functional decline.
What you'll learn
How mitochondrial dysfunction contributes to vascular ageing
Why mitochondrial reactive oxygen species can impair endothelial function
Why conventional antioxidants may not adequately target mitochondrial oxidative stress
How mitochondria-targeted antioxidants differ from non-targeted antioxidants
How Mitoquinol reaches and accumulates within mitochondria
What human clinical research has found in vascular ageing and endothelial dysfunction
Which questions remain for future mitochondrial therapeutic research
Mitochondrial dysfunction and vascular aging
Mitochondrial dysfunction is recognised as one of the interconnected hallmarks of ageing and is thought to contribute to many of the physiological changes that occur over time.¹ Beyond producing adenosine triphosphate, mitochondria regulate redox signalling, calcium homeostasis, inflammation, cellular stress responses and programmed cell death.
These functions are particularly important in the vascular endothelium, the single-cell layer lining the interior surface of blood vessels. Rather than acting as a passive barrier, the endothelium regulates vascular tone, blood flow, coagulation, immune-cell trafficking and communication between circulating factors and the vessel wall.
Age-related endothelial dysfunction is characterised in part by reduced nitric oxide bioavailability and a diminished capacity of blood vessels to dilate appropriately. This functional decline can precede overt structural vascular disease, making endothelial function an important focus of vascular ageing research.
Mitochondrial oxidative stress is increasingly being investigated as one of the mechanisms contributing to this process. During normal oxidative phosphorylation, mitochondria generate reactive oxygen species, or ROS. At physiological concentrations, these molecules participate in normal redox signalling. When mitochondrial ROS generation exceeds the capacity of cellular antioxidant and repair systems, however, redox signalling can become disrupted and oxidative damage can accumulate.²
Within the vascular endothelium, excess mitochondrial ROS can interact with nitric oxide or alter the pathways responsible for nitric oxide production and signalling. Reduced nitric oxide bioavailability limits endothelium-dependent vasodilation and may contribute to progressive changes in arterial function.
This creates a potentially self-reinforcing process. Mitochondrial oxidative stress can impair mitochondrial proteins, lipids and DNA, while damaged or dysfunctional mitochondria may generate further ROS.² For vascular researchers, this raises an important therapeutic question: can oxidative stress be modulated within mitochondria themselves, rather than addressed only through broadly distributed antioxidant compounds?
Why mitochondrial ROS is not simply “oxidative stress”
Reactive oxygen species are sometimes presented only as damaging metabolic by-products. In reality, ROS also act as signalling molecules that help cells adapt to exercise, nutrient availability, immune activation and other physiological stressors.
The biological effect of ROS therefore depends on where the ROS is produced, which reactive species is involved, its local concentration, the duration of exposure, the antioxidant and repair capacity of the surrounding cellular compartment, and whether ROS production is transient and adaptive or sustained and dysregulated.
This distinction is one reason why broadly suppressing ROS throughout the body is unlikely to reproduce the effects of selectively modulating mitochondrial redox balance.
In vascular ageing, the therapeutic objective is not necessarily to eliminate ROS. It is to reduce excessive or dysregulated mitochondrial ROS while preserving the physiological redox signals required for vascular adaptation and normal cellular function.
This location-specific understanding of redox biology has helped drive interest in mitochondria-targeted antioxidants and other interventions designed to act within specific mitochondrial compartments.
Why researchers are looking beyond conventional antioxidants
Conventional antioxidants are generally absorbed and distributed across tissues without a mechanism that directs them selectively into mitochondria. Even when an antioxidant reaches the circulation, this does not necessarily mean that a biologically relevant concentration reaches the inner mitochondrial membrane.
This delivery problem is especially important because the inner mitochondrial membrane is both a major site of mitochondrial ROS generation and a highly specialised biological barrier. To influence oxidative processes occurring there, a compound must cross the plasma membrane, enter the cell, cross the mitochondrial outer membrane and then accumulate across the inner mitochondrial membrane.
The mixed outcomes reported across conventional antioxidant research have also encouraged a more nuanced view of oxidative stress. Antioxidant activity measured in vitro does not automatically translate into effective modulation of redox biology in humans. The location, concentration and timing of an antioxidant intervention can all influence its biological effects.
Mitochondria-targeted antioxidant research therefore represents a shift from asking whether a molecule has antioxidant properties to asking whether it reaches the relevant subcellular compartment and influences a defined mechanism.
This approach has produced a broader category of investigational compounds designed to concentrate within mitochondria through carrier systems such as lipophilic cations, peptides or other mitochondrial delivery technologies.³
What are mitochondria-targeted antioxidants?
Mitochondria-targeted antioxidants are compounds designed to accumulate preferentially within mitochondria rather than remaining broadly distributed throughout the cell.
One of the most extensively researched approaches uses the lipophilic triphenylphosphonium cation, commonly abbreviated as TPP⁺. Because TPP⁺ is positively charged and sufficiently lipophilic to cross biological membranes, it can be drawn into the negatively charged mitochondrial matrix by the mitochondrial membrane potential.³
The mitochondrial inner membrane typically maintains a substantial negative potential relative to the cytosol. Lipophilic cations can therefore accumulate within mitochondria according to the electrochemical gradient described by the Nernst relationship. This enables a bioactive compound attached to TPP⁺ to reach concentrations within mitochondria that would not be achieved through passive systemic distribution alone.³˒⁴
Importantly, mitochondria-targeted antioxidants are not a single therapeutic class with interchangeable effects. Their activity depends on the antioxidant or bioactive group attached to the targeting moiety, the length and hydrophobicity of the linker, the administered dose, tissue distribution and the biological context in which the compound is studied.
What is Mitoquinol?
Mitoquinol is a mitochondria-targeted form of ubiquinol developed to accumulate at the inner mitochondrial membrane. It combines a ubiquinol antioxidant group with a lipophilic TPP⁺ cation through a shortened carbon linker.⁴
The term MitoQ is commonly used to describe the redox pair formed by Mitoquinol, the reduced form, and mitoquinone, the oxidised form.
After entering cells and accumulating within mitochondria, the compound localises predominantly to the mitochondrial inner membrane. Its ubiquinol component can donate electrons during antioxidant activity and is subsequently converted to mitoquinone. Mitoquinone can then be reduced back to mitoquinol by the mitochondrial respiratory chain, allowing the molecule to participate in repeated redox cycling.⁴
This recycling mechanism distinguishes Mitoquinol from an antioxidant molecule that is irreversibly consumed following a single redox reaction.
Mitoquinol is therefore being investigated not simply as a source of CoQ10-related antioxidant activity, but as a targeted redox intervention designed to influence oxidative processes within mitochondria.
How Mitoquinol reaches the mitochondria
Mitoquinol contains three principal structural components: a ubiquinol antioxidant group that participates in redox reactions, a shortened carbon linker that influences hydrophobicity and membrane behaviour, and a TPP⁺ targeting group that drives mitochondrial accumulation.
The TPP⁺ group can pass through phospholipid bilayers because its positive charge is distributed across a large, lipophilic structure. Once inside the cell, the mitochondrial membrane potential drives further accumulation across the inner mitochondrial membrane.³˒⁴
The hydrophobicity of the complete molecule must be carefully balanced. If a mitochondria-targeted compound is insufficiently lipophilic, it may not cross membranes efficiently. If it is excessively hydrophobic, it may bind non-specifically to other membranes or display altered pharmacokinetic behaviour. Research into MitoQ analogues demonstrated that linker structure and hydrophobicity can materially affect mitochondrial uptake and biological activity.⁵
Once accumulated, Mitoquinol associates with the inner mitochondrial membrane. This places its redox-active ubiquinol component near the membrane environment in which electron transport and mitochondrial ROS generation occur.
How does Mitoquinol differ from CoQ10?
Coenzyme Q10 is an endogenous component of the mitochondrial electron transport chain. It transfers electrons between respiratory complexes and also contributes to antioxidant defence in its reduced ubiquinol form. Mitoquinol retains a ubiquinol-derived redox-active group but differs structurally and pharmacologically from conventional CoQ10. It has a shortened carbon chain, is conjugated to a TPP⁺ targeting group, is designed to concentrate at the mitochondrial inner membrane and is investigated as a distinct chemical entity rather than as a conventional CoQ10 formulation.
Standard CoQ10 and ubiquinol supplements do not possess the same TPP⁺ targeting group. Their presence in the bloodstream therefore does not establish equivalent mitochondrial delivery or accumulation. For researchers, this distinction is essential. Mitoquinol should not be treated simply as a more bioavailable CoQ10 supplement. It is a modified, mitochondria-targeted molecule with its own uptake characteristics, dosing evidence and clinical research programme.
Schematic diagram illustrating the selective uptake of MitoQ into the cytoplasm driven by the plasma membrane potential (∆ψ p ) and its subsequent further accumulation by mitochondria driven by the mitochondrial membrane potential (∆ψ m ). Within mitochondria, this several-hundredfold accumulation of MitoQ relative to its concentration in the external fluid will protect the organelle from oxidative damage far more effectively than untargeted antioxidants.
From mechanistic tool to investigational mitochondrial therapeutic
The first studies of TPP⁺-conjugated ubiquinone compounds were designed to determine whether a redox-active molecule could be delivered selectively into mitochondria. Early cellular research demonstrated mitochondrial accumulation and antioxidant activity, while subsequent in vivo work showed that TPP⁺ conjugation could be used to deliver bioactive molecules to mitochondria in living animals.⁴˒⁶
Preclinical cardiovascular research provided further evidence that mitochondrial targeting could produce measurable vascular effects. In stroke-prone spontaneously hypertensive rats, eight weeks of MitoQ₁₀ treatment improved thoracic aortic nitric oxide bioavailability, reduced systolic blood pressure and attenuated cardiac hypertrophy compared with control interventions.⁷ These findings supported a relationship between mitochondrial oxidative stress and vascular dysfunction but, as evidence from an animal model, could not establish clinical efficacy in humans.
Together, these studies established MitoQ as an important research tool in mitochondrial redox biology. They also helped create the foundation for investigating whether mitochondrial targeting could produce measurable effects in human physiology.
The term mitochondrial therapeutic is useful in this context, but it requires careful interpretation. Mitoquinol is being investigated as a mitochondria-targeted intervention across multiple research settings. This does not mean that clinical efficacy has been established across all conditions associated with mitochondrial dysfunction.
The strength of the evidence varies by population or experimental model, dose, treatment duration, endpoint, evidence type, study purpose and independent replication. The most appropriate scientific framing is that Mitoquinol is an investigational mitochondria-targeted therapeutic strategy supported by mechanistic, preclinical and selected human evidence.
Mitoquinol and vascular ageing
One of the most informative human studies was a randomised, double-blind, placebo-controlled crossover trial conducted by Rossman and colleagues in healthy older adults aged 60 to 79 years. Participants received 20 mg per day of MitoQ for six weeks or placebo, with a washout period between interventions.⁸
The trial assessed brachial artery flow-mediated dilation, a functional measure of endothelium-dependent vasodilation. MitoQ supplementation improved flow-mediated dilation relative to placebo. The researchers also reported reduced oxidised low-density lipoprotein and an improvement in aortic stiffness among participants who had elevated stiffness at baseline.⁸
Mechanistic experiments conducted within the study supported a relationship between the functional response and mitochondrial oxidative stress. Important limitations include the small study population, six-week treatment period, use of vascular-function rather than cardiovascular-event outcomes, and inclusion of older adults without diagnosed cardiovascular disease.
The trial nevertheless provided controlled human evidence that a mitochondria-targeted antioxidant could influence a recognised measure of endothelial function.
A subsequent analysis investigated whether changes in circulating factors following MitoQ supplementation affected endothelial cells studied ex vivo. Serum collected after MitoQ treatment reduced cellular and mitochondrial oxidative stress and improved nitric oxide-related endothelial-cell function compared with serum collected after placebo.⁹
These findings provide additional mechanistic support but should not be interpreted as an independent clinical efficacy trial because the analysis was linked to the original study population.
Image taken from Rossman et al., 2018.
Figure 2. Brachial artery flow–mediated dilation (BAFMD) expressed as percent (left) and absolute (right) change after 6 weeks of placebo or MitoQ supplementation. Values are presented as mean±SEM, with individual responses below. *P<0.05 vs placebo.
Mitoquinol and Peripheral Artery Disease (PAD)
A randomised crossover study investigated the acute effects of an 80 mg dose of MitoQ in people with peripheral artery disease. The researchers examined vascular function, antioxidant enzyme activity and treadmill walking outcomes.¹⁰ The study reported acute improvements in brachial and popliteal artery flow-mediated dilation and changes in exercise-related outcomes following MitoQ administration. Because the study assessed a single 80 mg dose, its findings cannot be directly extrapolated to chronic supplementation at lower daily doses.
The research is nevertheless relevant to mitochondrial therapeutic development because it examined MitoQ in a population with impaired vascular function and elevated oxidative stress rather than in a healthy athletic population. It also illustrates an important research question: whether responses to mitochondria-targeted antioxidants depend on baseline physiology. This remains a hypothesis that should be tested prospectively rather than assumed across populations.
Image taken from Park et al., 2020.
Mitoquinol and hypertension
A randomised study examined MitoQ supplementation and endurance exercise training in adults with hypertension. The researchers evaluated cardiovascular measures alongside biomarkers related to oxidative stress, inflammation and microRNA signalling.¹¹
The study reported improvements across several measured outcomes, with some of the strongest changes observed when MitoQ was combined with exercise training. However, its design and population differ from the healthy older-adult vascular ageing trial, and the findings should not be generalised to other cardiovascular populations without further research.
The exercise component is scientifically relevant because exercise itself alters mitochondrial biogenesis, redox signalling, antioxidant defence and vascular function. Potential interactions between exercise and a mitochondria-targeted antioxidant may therefore differ according to dose, training status, exercise intensity and baseline health.
MitoQ should not be assumed to reproduce the effects of exercise or replace established lifestyle and clinical interventions.
Image taken from Masoumi-Ardakani et al., 2022.
Does Mitoquinol improve exercise performance?
The same mitochondrial oxidative stress implicated in vascular dysfunction also plays out during exercise, where intense muscle contraction sharply increases ROS production and places transient strain on the same redox systems. Studies have examined different populations, dosing strategies and outcomes, including cycling performance, peak power, exercise tolerance, redox signalling and exercise-induced oxidative damage.
In middle-aged, recreationally trained male cyclists, 28 days of MitoQ supplementation at 20 mg/day produced a modest but statistically significant improvement in 8 km cycling performance. Participants completed the time trial 1.3% faster and generated 4.4% greater average power than with placebo.¹²
In healthy men performing high-intensity intermittent exercise, 21 days of supplementation at 20 mg/day attenuated mitochondrial and nuclear DNA damage in skeletal muscle and lymphocytes. A single acute dose did not produce the same effect.¹³
MitoQ at 20 mg/day augmented the acute exercise-induced increase in skeletal-muscle PGC-1α mRNA and produced a greater training-induced improvement in peak power. However, it did not produce additional improvements in VO₂peak or 20 km time-trial performance and did not alter training-induced mitochondrial content or respiratory function.¹⁴
A 2024 systematic review and meta-analysis identified eight studies involving 188 participants. It reported an overall reduction in exercise-induced oxidative damage but no overall improvement in endurance performance; a sensitivity analysis indicated a possible exercise-tolerance benefit in people with peripheral artery disease.¹⁵
This pooled conclusion should be interpreted alongside the distinct populations, doses and endpoints examined in the primary studies. You can learn more about Mitoquinol and exercise performance by visiting our clinical trial library.
Which populations may be most responsive to Mitoquinol?
Current findings suggest that baseline oxidative stress, endothelial function, cardiorespiratory fitness and disease status may influence the physiological response to Mitoquinol. This does not yet allow researchers to define a single responder phenotype. It does, however, support testable questions about whether effects are larger in people with impaired endothelial function, whether elevated baseline mitochondrial oxidative stress predicts response, whether cardiorespiratory fitness modifies effects, and which biomarkers can identify target engagement. Answering these questions will be important if mitochondria-targeted antioxidants are to move from broad supplementation research towards more targeted and mechanistically informed clinical use.
Ongoing research: Mitoquinol and vascular ageing
Clinical research continues to examine whether the vascular effects observed in small proof-of-concept studies can be replicated in larger and longer trials. A phase IIa trial conducted by researchers at the University of Colorado Boulder evaluated 20 mg per day of MitoQ for three months in older adults. Its prespecified outcomes included endothelium-dependent dilation, aortic stiffness, endothelial mitochondrial health and markers of oxidative stress.¹⁶ The ClinicalTrials.gov record lists the study as completed but does not currently report study results.¹⁷
Other registered studies have investigated or are investigating MitoQ in areas including frailty, mobility, cerebrovascular function and peripheral artery disease. Registered protocols indicate what researchers intend to study, but registration alone is not evidence that an intervention is effective. These trials reflect a broader shift in mitochondrial medicine. Investigators are increasingly asking whether mitochondrial target engagement translates into meaningful changes in vascular function, mobility, cognitive or cerebrovascular function, functional independence, quality of life and longer-term clinical outcomes.
What does the current evidence support?
The current evidence supports Mitoquinol as a scientifically credible mitochondria-targeted antioxidant and an investigational tool for studying mitochondrial oxidative stress in humans. Controlled human studies show effects on endothelial function and selected oxidative-stress, exercise-tolerance, performance and adaptation outcomes in specific populations.⁸˒¹⁰˒¹²˒¹³˒¹⁴ The evidence is not sufficient to conclude that Mitoquinol prevents cardiovascular disease or universally improves exercise performance. For clinicians and researchers, its principal significance lies in the strategy it represents: directing a redox-active compound towards mitochondria to modulate oxidative stress within a defined subcellular compartment.
Conclusion
Mitochondrial dysfunction is increasingly recognised as an important contributor to vascular ageing. Excess mitochondrial ROS can disrupt nitric oxide signalling, impair endothelial function and contribute to age-related changes in arterial physiology. Mitoquinol was developed to address a central limitation of conventional antioxidants: the difficulty of delivering an active redox compound to mitochondria at a meaningful concentration. Through its TPP⁺ targeting group, Mitoquinol accumulates at the mitochondrial inner membrane, where it can participate in redox cycling and influence mitochondrial oxidative processes.
Early human trials provide proof-of-concept that this approach can alter endothelial function and selected markers of oxidative stress in defined populations. However, the evidence remains population-specific, and long-term clinical outcomes have not been established. Mitoquinol should therefore be understood neither as conventional CoQ10 nor as a universally proven treatment for mitochondrial dysfunction. It is better characterised as a mitochondria-targeted therapeutic strategy with a growing mechanistic and clinical research base.
As mitochondrial medicine advances, the central question will not simply be whether an intervention is an antioxidant. It will be whether it reaches the relevant mitochondrial compartment, engages the intended biological target and produces a meaningful functional or clinical effect.
FAQs
What is Mitoquinol?
Mitoquinol is a targeted mitochondrial antioxidant that has been evaluated in multiple randomised, placebo-controlled human clinical trials³, most commonly at daily doses of 10–20mg, and used in aging and disease research to combat oxidative stress and support mitochondrial health. It's a modified form of ubiquinol (the active form of CoQ10) that's been chemically altered to concentrate specifically inside mitochondria, the energy-producing structures within our cells, rather than circulating more generally throughout the body.
How does Mitoquinol differ from CoQ10?
Both compounds share the same antioxidant core, but their behaviour in the body differs significantly. Standard CoQ10 (and its active form, ubiquinol) is absorbed and distributed throughout the body, with only a small fraction reaching mitochondria. Mitoquinol is engineered with an added chemical component (a triphenylphosphonium, or TPP+, group) that acts like a molecular delivery tag, allowing it to cross both the cell membrane and the mitochondrial membrane and accumulate at much higher concentrations inside mitochondria specifically⁴. This targeted delivery is the central distinction driving the clinical interest in Mitoquinol as a distinct compound rather than simply "more CoQ10."
What is a mitochondria-targeted antioxidant?
A mitochondria-targeted antioxidant is a compound designed to concentrate specifically within mitochondria, rather than being distributed evenly throughout the cell or bloodstream. Because mitochondria are a primary site of reactive oxygen species (ROS) production, a mitochondria-targeted antioxidant is positioned to intercept and neutralise oxidative damage closer to its source, rather than relying on diffuse, whole-body antioxidant activity.
Why target antioxidants to mitochondria?
Mitochondria are both the main energy producers in our cells and one of the main sources of oxidative stress, since reactive oxygen species are a natural byproduct of the energy-production process. These mechanisms underpin the use of mitochondria-targeted antioxidants in aging and longevity research models, with findings supporting the role of mitochondrial oxidative stress in vascular aging and endothelial dysfunction specifically³. Conventional, non-targeted antioxidants taken orally are largely diluted before they ever reach mitochondria in meaningful concentrations, since only a small fraction of what's absorbed makes it past the mitochondrial membrane.
By comparison, compounds designed to actively accumulate within mitochondria — MitoQ has demonstrated good tolerability and consistent biological effects aligned with mitochondrial redox modulation across studies¹³, and importantly, does not blunt physiological exercise adaptations, making it valuable for studying redox signalling rather than producing indiscriminate antioxidant effects — offer researchers a more precise tool for studying and potentially addressing oxidative stress right where a substantial share of it originates.
References
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. https://doi.org/10.1016/j.cell.2022.11.001
Murphy MP. How mitochondria produce reactive oxygen species. Biochemical Journal. 2009;417(1):1-13. https://doi.org/10.1042/BJ20081386
Murphy MP, Smith RAJ. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annual Review of Pharmacology and Toxicology. 2007;47:629-656. https://doi.org/10.1146/annurev.pharmtox.47.120505.105110
Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. Journal of Biological Chemistry. 2001;276(7):4588-4596. https://doi.org/10.1074/jbc.M009093200
Asin-Cayuela J, Manas AR, James AM, Smith RAJ, Murphy MP. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Letters. 2004;571(1-3):9-16. https://doi.org/10.1016/j.febslet.2004.06.045
Smith RAJ, Porteous CM, Gane AM, Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proceedings of the National Academy of Sciences USA. 2003;100(9):5407-5412. https://doi.org/10.1073/pnas.0931245100
Graham D, Huynh NN, Hamilton CA, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54(2):322-328. https://doi.org/10.1161/HYPERTENSIONAHA.109.130351
Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71(6):1056-1063. https://doi.org/10.1161/HYPERTENSIONAHA.117.10787
Murray KO, Ludwig KR, Darvish S, Coppock ME, Seals DR, Rossman MJ. Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress. American Journal of Physiology-Heart and Circulatory Physiology. 2023;325(1):H187-H194. https://doi.org/10.1152/ajpheart.00191.2023
Park SY, Pekas EJ, Headid RJ, et al. Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease. American Journal of Physiology-Heart and Circulatory Physiology. 2020;319(2):H456-H467. https://doi.org/10.1152/ajpheart.00235.2020
Masoumi-Ardakani Y, Najafipour H, Nasri HR, Aminizadeh S, Jafari S. Moderate endurance training and MitoQ improve cardiovascular function, oxidative stress, and inflammation in hypertensive individuals: the role of miR-21 and miR-222. Cell Journal. 2022;24(9). https://www.celljournal.org/article_253351.html
Gonzalo-Skok O, Casuso RA. Effects of Mitoquinone (MitoQ) supplementation on aerobic exercise performance and oxidative damage: a systematic review and meta-analysis. Sports Medicine – Open. 2024;10:79. https://doi.org/10.1186/s40798-024-00741-5
Murray KO, Berryman-Maciel M, Darvish S, Coppock ME, You Z, Chonchol M, Seals DR, Rossman MJ. Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans: a study protocol. Frontiers in Physiology. 2022;13:980783. https://doi.org/10.3389/fphys.2022.980783
ClinicalTrials.gov. Mitochondrial-Targeted Antioxidant Supplementation for Improving Age-Related Vascular Dysfunction in Humans (NCT04851288). https://clinicaltrials.gov/study/NCT04851288
